Latest News and Press Releases

SALT LAKE CITY, July 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has closed a five-year...

SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings...

SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has received the Great...

Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testingEarly access via large-scale clinical study to establish the...

SALT LAKE CITY, June 02, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced new molecular residual...

SALT LAKE CITY, May 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced it will share data from seven new...

SALT LAKE CITY, May 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that management plans to...

SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology...

Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew...

SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective,...